(via NewsDirect)
Sowemimo-Coker explains that OCT461201 is the most advanced of the company's four programmes. The trial, conducted in collaboration with
She says "since then we've been crunching the numbers and just processing those healthy volunteers to make sure we are in good shape and I'm very pleased to report [that we're] absolutely fine, no adverse events and all looking good from a safety and tolerability point of view - so that objective absolutely met."
Sowemimo-Coker emphasises that while the compound binds to a cannabinoid receptor, it's technically not a cannabinoid but a new chemical entity. The company aims to treat chemotherapy-induced peripheral neuropathy (CIPN) with this compound, a condition affecting 60% of chemotherapy patients.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source